Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

This study is testing whether elranatamab — a drug that helps the immune system find and kill multiple myeloma cells — can be given less frequently and in an outpatient (clinic visit, not hospital) setting for people whose myeloma has come back or stopped responding to treatment. **You may be eligible if...** - You have multiple myeloma that has relapsed (come back) or is refractory (not responding) to prior treatments - You have received at least one prior treatment for myeloma - Your myeloma is measurable in blood, urine, or lab tests - You are in acceptable overall health **You may NOT be eligible if...** - You have never had myeloma treatment before - You have serious organ problems (heart, liver, kidneys) - You have active infections or certain other cancers - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.